HomeVideoWilliam A. Sarraille|Sidley Austin LLP| USA| Biosimilars 2015 | Conference Series LLC 

William A. Sarraille|Sidley Austin LLP| USA| Biosimilars 2015 | Conference Series LLC 

4th International Conference and Exhibition on Biologics and Biosimilars October 26-28, 2015 Baltimore, USA

Scientific Talk On: Exploring Government Pricing and Reimbursement Policy Challenges Associated with Biosimilars

Click here for Abstract and Biography:http://biosimilars-biologics.pharmaceuticalconferences.com/abstract/2015/exploring-government-pricing-and-reimbursement-policy-challenges-associated-with-biosimilars

Conference Series LLC (3000+ Global Events): conferenceseries.com 
Global Medical Conferences: conferenceseries.com
Global Nursing Conferences: nursingconference.com
Global Pharmaceutical Conferences: pharmaceuticalconferences.com
Global Cancer Conferences: cancersummit.org 
Global Diabetes Conferences: diabetesexpo.com 
Global Dental Conferences: dentalcongress.com 
700+ Open Access Journals: omicsonline.org 


BILL SARRAILLE is a senior member of the Healthcare Practice group and a nationally-recognized lawyer in healthcare law. Mr. Sarraille concentrates on a variety of healthcare matters, including Medicare and Medicaid reimbursement, coverage and coding, pharmaceutical price reporting, issues related to the marketing and promotion of pharmaceuticals and medical devices, internal investigations, clinical research issues, Stark and Anti-Kickback Law analyses, Medicare and Medicaid audits, healthcare acquisitions and due diligence, compliance program audits, managed care matters, healthcare contracts, administrative litigation, legislative matters, coverage for new devices and services, the representation of witnesses and companies before Congressional Committees, and the defense of healthcare criminal and False Claims Act matters.


The Biologics Price Competition and Innovation Act (BPCIA) was signed into law on March 23, 2010 as part of the Patient Protection and Affordable Care Act (PPACA). BPCIA’s announcement of a new Food and Drug Administration (FDA) regulatory pathway for the approval of biosimilar products has created several government pricing and reimbursement policy challenges. The proposed presentation will discuss the coverage, reimbursement, and related strategy questions from the perspective of both an experienced reimbursement counsel and a reference product manufacturer. Reimbursement issues discussed during this joint presentation will include the impact of Average Sales Price (ASP) and non-ASP reimbursement systems and the crucial distinction between the biosimilar and interchangeability standards. The potential for National Coverage Determinations, Local Coverage Determinations, and innovation reimbursement reforms will also be discussed, as will value-based contracting approaches.

Likes: 0

Viewed: 0


Previous post
What I need to Know About Eating and Type 2 Diabetes Review Dr Gary M Levin
Next post
What Are The Early Signs Of Diabetes

Leave a Reply

Be the First to Comment!

Notify of